For NSCLC patients with targetable driver mutations, a retrospective study showed that PD-L1 inhibitor followed by osimertinib instead of other EGFR–TKIs resulted in severe irAEs, especially among patients who received PD-L1 blockade recently, suggesting the importance of appropriate sequence of ICI immunotherapy and osimertinib (30). This evidence concerns the gene EGFR and non-small cell lung carcinoma.